“…Current investigations have also synthesized IONPs employing different shells with anticancer agents conventionally administered, such as β-cyclodextrin [ 135 ], carmustine [ 136 ], cetuximab [ 137 , 138 , 139 ], cytarabine [ 140 ], daunomycin [ 141 ], docetaxel [ 142 , 143 ], epirubicin [ 144 ], 5-fluorouracil [ 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 ], gemcitabine [ 22 , 154 , 155 , 156 , 157 , 158 ], methotrexate [ 159 , 160 , 161 ], mitoxantrone [ 162 , 163 , 164 , 165 ] and paclitaxel [ 27 , 104 , 166 , 167 , 168 , 169 , 170 , 171 , 172 ]. It is noteworthy, however, that these nanosystems demonstrate magnetic properties only in the presence of external magnetic fields to prevent agglomerations of nanoparticles [ 111 ] and to allow a satisfactory performance in the target sites.…”